E Jonasch1, I E McCutcheon2, S G Waguespack3, S Wen4, D W Davis5, L A Smith6, N M Tannir6, D S Gombos7, G N Fuller8, S F Matin9. 1. Departments of Genitourinary Medical Oncology. Electronic address: ejonasch@mdanderson.org. 2. Neurosurgery. 3. Endocrine Neoplasia and Hormonal Disorders. 4. Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston. 5. ApoCell, Inc, Houston. 6. Departments of Genitourinary Medical Oncology. 7. Departments of Ophthalmology. 8. Pathology. 9. Urology, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
Abstract
BACKGROUND: Von Hippel-Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHL patients and examined the expression of candidate receptors in archived tissue. METHODS: Patients with VHL were given four cycles of 50 mg sunitinib daily for 28 days, followed by 14 days off. Primary end point was toxicity. Modified RECIST were used for efficacy assessment. We evaluated 20 archival renal cell carcinomas (RCCs) and 20 hemangioblastomas (HBs) for biomarker expression levels using laser-scanning cytometry (LSC). RESULTS: Fifteen patients were treated. Grade 3 toxicity included fatigue in five patients. Dose reductions were needed in 10 patients. Eighteen RCC and 21 HB lesions were evaluable. Six of the RCCs (33%) responded partially, versus none of the HBs (P = 0.014). LSC revealed that mean levels of phosphorylated vascular endothelial growth factor receptor-2 were lower in HB than in RCC endothelium (P = 0.003) and mean phosphorylated fibroblast growth factor receptor substrate-2 (pFRS2) levels were higher in HB (P = 0.003). CONCLUSIONS: Sunitinib treatment in VHL patients showed acceptable toxicity. Significant response was observed in RCC but not in HB. Greater expression of pFRS2 in HB tissue than in RCC raises the hypothesis that treatment with fibroblast growth factor pathway-blocking agents may benefit patients with HB.
BACKGROUND:Von Hippel-Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHLpatients and examined the expression of candidate receptors in archived tissue. METHODS:Patients with VHL were given four cycles of 50 mg sunitinib daily for 28 days, followed by 14 days off. Primary end point was toxicity. Modified RECIST were used for efficacy assessment. We evaluated 20 archival renal cell carcinomas (RCCs) and 20 hemangioblastomas (HBs) for biomarker expression levels using laser-scanning cytometry (LSC). RESULTS: Fifteen patients were treated. Grade 3 toxicity included fatigue in five patients. Dose reductions were needed in 10 patients. Eighteen RCC and 21 HB lesions were evaluable. Six of the RCCs (33%) responded partially, versus none of the HBs (P = 0.014). LSC revealed that mean levels of phosphorylated vascular endothelial growth factor receptor-2 were lower in HB than in RCC endothelium (P = 0.003) and mean phosphorylated fibroblast growth factor receptor substrate-2 (pFRS2) levels were higher in HB (P = 0.003). CONCLUSIONS:Sunitinib treatment in VHLpatients showed acceptable toxicity. Significant response was observed in RCC but not in HB. Greater expression of pFRS2 in HB tissue than in RCC raises the hypothesis that treatment with fibroblast growth factor pathway-blocking agents may benefit patients with HB.
Authors: Srinivasan Madhusudan; Gaël Deplanque; Jeremy P Braybrooke; Emma Cattell; Marian Taylor; Pat Price; Marie D Tsaloumas; Niall Moore; Susan M Huson; Chris Adams; Peggy Frith; Paul Scigalla; Adrian L Harris Journal: JAMA Date: 2004-02-25 Impact factor: 56.272
Authors: Raju R Raval; Kah Weng Lau; Maxine G B Tran; Heidi M Sowter; Stefano J Mandriota; Ji-Liang Li; Christopher W Pugh; Patrick H Maxwell; Adrian L Harris; Peter J Ratcliffe Journal: Mol Cell Biol Date: 2005-07 Impact factor: 4.272
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe Journal: Nature Date: 1999-05-20 Impact factor: 49.962
Authors: Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531
Authors: Thomas E Hutson; Ian D Davis; Jean-Pascal H Machiels; Paul L De Souza; Sylvie Rottey; Bao-Fa Hong; Richard J Epstein; Katherine L Baker; Lauren McCann; Theresa Crofts; Lini Pandite; Robert A Figlin Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Harriet M Kluger; Summar F Siddiqui; Cesar Angeletti; Mario Sznol; William K Kelly; Annette M Molinaro; Robert L Camp Journal: Lab Invest Date: 2008-07-14 Impact factor: 5.662
Authors: Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman Journal: Eur Urol Date: 2019-07-18 Impact factor: 20.096
Authors: Eric Jonasch; Ian E McCutcheon; Dan S Gombos; Kamran Ahrar; Nancy D Perrier; Diane Liu; Christine C Robichaux; Mercedes F Villarreal; Justin A Weldon; Ashley H Woodson; Patrick G Pilie; Gregory N Fuller; Steven G Waguespack; Surena F Matin Journal: Lancet Oncol Date: 2018-09-17 Impact factor: 41.316
Authors: Ana Martins Metelo; Haley R Noonan; Xiang Li; Youngnam Jin; Rania Baker; Lee Kamentsky; Yiyun Zhang; Ellen van Rooijen; Jordan Shin; Anne E Carpenter; Jing-Ruey Yeh; Randall T Peterson; Othon Iliopoulos Journal: J Clin Invest Date: 2015-04-13 Impact factor: 14.808